<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>356</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15378069</PubmedId>
            <Abstract>Integrins are important adhesion receptors in all Metazoa that transmit conformational change bidirectionally across the membrane. Integrin alpha and beta subunits form a head and two long legs in the ectodomain and span the membrane. Here, we define with crystal structures the atomic basis for allosteric regulation of the conformation and affinity for ligand of the integrin ectodomain, and how fibrinogen-mimetic therapeutics bind to platelet integrin alpha(IIb)beta3. Allostery in the beta3 I domain alters three metal binding sites, associated loops and alpha1- and alpha7-helices. Piston-like displacement of the alpha7-helix causes a 62 degrees reorientation between the beta3 I and hybrid domains. Transmission through the rigidly connected plexin/semaphorin/integrin (PSI) domain in the upper beta3 leg causes a 70 A separation between the knees of the alpha and beta legs. Allostery in the head thus disrupts interaction between the legs in a previously described low-affinity bent integrin conformation, and leg extension positions the high-affinity head far above the cell surface.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>59-67</ArticlePages>
            <ArticleTitle>Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Xiao</LastName>
                    <ForeName>Tsan</ForeName>
                </Author>
                <Author>
                    <LastName>Takagi</LastName>
                    <ForeName>Junichi</ForeName>
                </Author>
                <Author>
                    <LastName>Coller</LastName>
                    <ForeName>Barry S</ForeName>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jia-Huai</ForeName>
                </Author>
                <Author>
                    <LastName>Springer</LastName>
                    <ForeName>Timothy A</ForeName>
                </Author>
            </Authors>
            <Affiliations>The CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, 200 Longwood Avenue, Boston, Massachusetts 02115, USA.</Affiliations>
            <ArticleChemicalList>Ligands;Platelet Glycoprotein GPIIb-IIIa Complex;Fibrinogen;Magnesium;Calcium</ArticleChemicalList>
            <ArticleMeshHeadingsList>Allosteric Regulation; Allosteric Site; Amino Acid Sequence; Biomimetic Materials(chemistry; metabolism); Calcium(metabolism); Crystallography, X-Ray; Fibrinogen(chemistry); Ligands; Magnesium(metabolism); Models, Molecular; Molecular Sequence Data; Platelet Glycoprotein GPIIb-IIIa Complex(chemistry; metabolism); Protein Structure, Quaternary; Protein Structure, Tertiary</ArticleMeshHeadingsList>
            <Comments>15525967  Nature. 2004 Nov 4;432(7013):27-8</Comments>
            <Journal>
                <Volume>432</Volume>
                <Issue>7013</Issue>
                <Title>Nature</Title>
                <Issn>1476-4687</Issn>
                <MedlineTa>Nature</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>10E5 Fab epitope on integrin αIIbβ3</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>R108, V110, Q113, N180, I185, N189, S237, R239, L244, H246</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>P08514.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Supplementary Table 1, Supplementary Figure 2 and PDB 2VDK (supersedes 1TY3)</LocationOfData>
                <EpitopeId>96042</EpitopeId>
                <ReferenceRegion>R77, V79, Q82, N149, I154, N158, S206, R208, L213, H215</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The source protein is part of the heterodimeric Integrin α&lt;sub&gt;IIb&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt;. The epitope is located on the Cap subdomain of α&lt;sub&gt;IIb&lt;/sub&gt; domain.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2, Supplementary Table 1, and Supplementary Figure 2</LocationOfData>
                        <BCellId>24208</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Protein-rich Platelets</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Six injections with 3 x 10^8 platelets 1 week apart, followed by one i.v. injection of 5 x 10^8 platelets.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The seven injections were performed with a citrated protein-rich platelet preparation obtained from a different donor for each injection.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.8</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The epitope-specific 10E5 Fab binds solely to the αIIb cap subdomain and has no effect on its conformation. Binding of small molecules is not blocked by 10E5, as shown by their co-crystallization, and thus the mAb blocks binding to fibrinogen solely by occluding the macromolecular recognition site on the αIIb cap subdomain. The complex of the soluble headpiece of Integrin αIIbβ3 (Integrin αIIb - chain A, and Integrin β3 - chain B) and the 10E5 Fab was crystallized in the presence of cacodylate. Also, other  structures were obtained as tertiary complexes with drugs that antagonize  fibrinogen binding: tirofiban [PDB: 2VDM supersedes 1TY5], eptifibatide [PDB: 2VDN supersedes 1TY6], and Merck compound L-739758 [PDB: 2VC2 supersedes 1TY7], which do not differ substantially from this complex structure.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>10E5</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>10E5</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>AAV27302.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>AAV27301.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Soluble α&lt;sub&gt;IIb&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt; headpiece</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRAEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGS</LinearSequence>
                                        <StartingPosition>32</StartingPosition>
                                        <EndingPosition>652</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P08514.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>2VDK</ComplexPdbId>
                            <AntibodyChain1PdbChain>H</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>L</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>A</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <CuratedContacts>
                                <EpitopeResidues>A: R77, V79, Q82, N149, I154, N158, S206, R208, L213, H215;</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: Y33:H1, Y57:H2, Y101:H3, D102:H3, Y103:H3, Y104:H3; L: Y49:L2, Y50:L2, Y91:L3;</AntibodyResiduesInteractingWithAntigen>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>A: R77, N78, V79, G80, S81, Q82, L84, N149, I154, N158, S205, S206, R208, P209, G210, I211, L213, W214, H215</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: D31, T32, Y33, Y57, Y101, D102, Y103, Y104; L: N32, Y49, Y50, N53, Y91, A92, Q93, L94</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>868.0</ContactAreaForAntigen>
                                <ContactAreaForAntibody>826.4</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

